These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26082452)

  • 1. Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.
    Lin Z; Schmidt CQ; Koutsogiannaki S; Ricci P; Risitano AM; Lambris JD; Ricklin D
    Blood; 2015 Aug; 126(7):891-4. PubMed ID: 26082452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C3dg-CR3 interaction in erythrophagocytosis.
    Roumenina LT
    Blood; 2015 Aug; 126(7):828-9. PubMed ID: 26272045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
    Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
    J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
    Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
    Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
    Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
    Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Parker CJ; Wiedmer T; Sims PJ; Rosse WF
    J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
    Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
    J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
    Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
    Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
    Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
    Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
    J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
    J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
    Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
    Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia.
    Lee M; Narayanan S; McGeer EG; McGeer PL
    PLoS One; 2014; 9(1):e87316. PubMed ID: 24489894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
    Risitano AM; Peffault de Latour R; Marano L; Frieri C
    Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.